LEGN customers relationship map

Legend Biotech (LEGN): How customer partnerships drive commercialization and revenue

Legend Biotech commercializes its lead CAR‑T therapy, CARVYKTI, through strategic collaborations and licensing agreements that convert clinical and regulatory progress into product sales and milestone/license revenue. The company monetizes primarily through a revenue‑share and commercialization framework with Johnson & Johnson/Janssen for CARVYKTI, supplemented by milestone and license fees from third‑party deals such as the Novartis agreement; these partner relationships are the operational and financial backbone as Legend scales treatment site activation and ex‑U.S. expansion. For more structured signals on partner coverage and document‑level sourcing, see the company’s summarized relationship record at NullExposure: https://nullexposure.com/.

How Legend’s business model actually works — concise investor thesis

Legend is a clinical‑stage biotech that has moved to commercial revenue by handing commercialization responsibilities to a large partner while retaining a meaningful economics stake. Revenue today is driven by CARVYKTI sales under the Janssen/Johnson & Johnson collaboration, while license and milestone receipts from other collaborations provide episodic upside and de‑risking capital. The operating model is partner‑centric: Legend focuses on discovery and early development, then leverages the scale and commercial capability of global pharma partners to drive product uptake and market penetration.

Primary revenue engine: CARVYKTI commercialization with Janssen/Johnson & Johnson.
Secondary revenue: milestone and license income from deals (Novartis cited), used to supplement and smooth product revenue.
Go‑to‑market posture: outsources large parts of commercialization and global roll‑out to partners, while retaining clinical development and program origination.

Explore the NullExposure customer record for more context: https://nullexposure.com/.

Operating model constraints and company‑level signals

NullExposure’s captured relationship excerpts do not include explicit contractual constraints such as exclusivity clauses or specific royalty rates, so all constraint commentary below is presented as company‑level signals rather than itemized contract terms.

Contracting posture: Legend operates with a collaboration‑first posture: the company consistently structures deals that place commercialization responsibility with a larger partner (Johnson & Johnson/Janssen), indicating a reliance on third‑party commercial execution rather than building a full global salesforce internally.
Concentration: Commercial revenue concentration is high. Multiple excerpts highlight Janssen/J&J as the central commercialization partner for CARVYKTI, signaling single‑partner concentration for the flagship product.
Criticality: Partner relationships are operationally critical—Janssen handles treatment site activation and global market roll‑out, making the partnership a critical path for revenue growth and ex‑U.S. expansion.
Maturity: The model shows movement from development to commercialization maturity: activated treatment sites, growing sales, and milestone recognition suggest the company’s revenue profile is transitioning from clinical funding to product sales and license income.

Customer relationship map — concise, source‑linked takeaways

Below are every relationship listed in the provided results, each with a plain‑English summary and a source reference.

Virginia Oncology Associates

Legend announced Virginia Oncology Associates as one of its early operational partners to roll out a targeted effort, highlighting local network engagement as part of expansion initiatives. According to the 2025 Q3 earnings call transcript (cited March 7, 2026), Virginia Oncology Associates is positioned as an early implementation partner.

Source: 2025 Q3 earnings call transcript (legn-2025q3-earnings-call), first cited March 7, 2026.

JNJ

Legend repeatedly references JNJ in public remarks as its principal commercialization partner for CARVYKTI, emphasizing joint efforts to increase patient access. The 2025 Q3 earnings call explicitly referred to working with Johnson & Johnson to bring CARVYKTI to more multiple myeloma patients (legn-2025q3-earnings-call, March 7, 2026).

Source: 2025 Q3 earnings call transcript (legn-2025q3-earnings-call), March 2026.

Johnson & Johnson

Johnson & Johnson functions as the named collaborator steering global commercialization and treatment‑site activation for CARVYKTI; Legend describes the partnership as central to market expansion and sales generation. Public company releases and press summaries across FY2025–FY2026 present J&J as the commercialization partner for CARVYKTI and credit the collaboration with enabling sales scale (company press releases and news coverage, FY2025–FY2026).

Source: Company filings and press releases cited in FY2025–FY2026 news coverage (GlobeNewswire and other outlets).

Janssen

The Janssen collaboration is the revenue driver for CARVYKTI sales recognized by Legend; the company reported a significant revenue increase tied to the “Janssen Agreement,” underlining Janssen’s role in product commercialization and revenue sharing. Legend’s FY2025–FY2026 reporting attributes a $109.6 million increase in revenue to CARVYKTI sales under the Janssen collaboration (GlobeNewswire release summarizing FY2025/FY2026 results, March–May 2026).

Source: Legend Biotech FY2025/FY2026 results and highlights (GlobeNewswire news release, March 10 and May 3, 2026).

Janssen Biotech

Analysts and market notes describe Janssen Biotech (a J&J subsidiary) as the operational collaborator enabling Legend’s market reach, framing the Janssen entity as the subsidiary executing commercialization and distribution tasks. Market commentary referencing FY2026 narratives highlights Janssen Biotech as the strategic collaborator extending Legend’s commercial footprint.

Source: Market commentary and analyst notes referenced in FY2026 market stories (MarketBeat and related coverage, March–May 2026).

Janssen (a J&J company)

Multiple analyst narratives summarize Legend’s economics as tied to a high‑stakes Janssen partnership, labeling the relationship the core revenue engine and value inflection point for investors. Investment write‑ups in FY2026 explicitly state that Legend’s revenue profile is anchored to the Janssen (a J&J company) collaboration for CARVYKTI commercialization.

Source: Investment narratives and sector write‑ups during FY2026 (SimplyWall.st community narratives and analyst coverage, FY2026).

Novartis

Legend has an exclusive global licensing agreement with Novartis to develop and commercialize LB2102 and other DLL3‑targeting CAR‑T therapies, a relationship that generates license revenue and milestone receipts that supplement product sales. The company referenced the Novartis licensing agreement during investor communications (earnings/press transcripts, FY2026).

Source: Earnings and investor communications referencing the Novartis licensing agreement (press transcript coverage, FY2026).

Key takeaways for investors and operators

Janssen/Johnson & Johnson is the single dominant commercialization partner, and CARVYKTI sales under that collaboration are the primary driver of reported revenue increases in FY2025–FY2026. This concentration creates both upside (leveraged global launch) and a partner‑dependency risk profile.
License and milestone income from other collaborators, notably Novartis, provide diversification of revenue sources and strategic validation of Legend’s discovery engine.
Operational execution is partner‑led: Legend’s financial performance and geographic expansion depend on partner activation of treatment sites and commercial scale‑up.
Local practice partnerships (e.g., Virginia Oncology Associates) underline ground‑level rollout strategy for increasing patient access and uptake in targeted markets.

What this means for investment and operational diligence

For investors, the investment thesis compresses to two linked facts: Legend’s near‑term earnings are driven by a high‑quality product commercialized by a large partner, and the upside from additional licensing deals accelerates margin inflection points. For operators evaluating counterparties, diligence should prioritize partner commercialization metrics (treatment‑site activation, distribution capabilities, and sales execution) and the cadence of milestone payments that feed Legend’s revenue line.

For a complete, source‑oriented customer relationship view and document traceability, visit the NullExposure customer record for Legend: https://nullexposure.com/.

Bold, partner‑centric dynamics define Legend’s commercial profile — that reality is the clearest signal for valuation and operational review.

LEGN customer relationships